اثر اریتروپوئتین دردرمان آنمی نارسی

Recombinant human erythropoietin (Epo) is known to accelerate&nbsp;erythropoesis in preterm infants. This study was designed to assess the effect&nbsp;of Epo in treatment of anemia of prematurity . Preterm infants with Hct <30% when infant&rsquo;s age was between 2 to 3&nbsp;weeks or Hct<25% when infant&rsquo;s age was more than 3 weeks , were divided&nbsp;randomly in two groups, each group included 10 babies. The mean&nbsp;gestational age in control group was 32.1&plusmn;1.85 weeks and birth weight was&nbsp;1489&plusmn;218 (SD) , grams and in case group was 31.5&plusmn;2.12 weeks and birth&nbsp;weight was 1367&plusmn;227 grams. Infants in case group received Epo 500 u/kg &nbsp;&nbsp; twice weekly for 4 weeks. All infants in control and case group were fed&nbsp;human milk and supplemented with entral iron prophylaxy. Levels of&nbsp;hematocrit andreticolocytes were determined for each infant at the beiging&nbsp;of study, 3 days after treatment and one week after the end of treatment.&nbsp;Weight, length and head circomference were determined weekly. The groups were significantly different in hematocrit and reticulocyes&nbsp;count at the end of study (P<0.0001 and P=0.024 respectively). In control&nbsp;group the prophylactic iron supplementation was not sufficient to prevent&nbsp;anemia and we found a significant decrease in hematocrit level at the end&nbsp;of study (P<0.0001). We concluded the early treatment of anemia of prematutiry with rhEpo&nbsp;with iron increase hematocrit and retyculocyte in perterm infants. If we can&nbsp;minimize blood sampling for laboratory analysis in preterm infants, treatment&nbsp;with Epo will reduce the need for blood transfusion in these infants.